Background: Pulmonary mucoepidermoid carcinoma (MEC) is an extremely rare pulmonary malignant tumor, its clinical features and conditions of prognosis is not entirely clear. The aim of this study is to discuss clinical features, diagnostic and therapeutic methods, and prognosis of pulmonary MEC.
Methods: We retrospectively studied 29 pulmonary MEC patients who diagnosed from January 2006 to December 2015 in Affiliated Hospital of Zhengzhou University. The clinical features, prognosis, diagnostic and therapeutic methods were analyzed.
Results: There were 20 patients identified as pulmonary MEC, which constitutes 0.18% of all the lung tumor patients. There were 18 males and 11 females, the median age of the patients was 45 years (range 10-79). There were 17 patients identified as high-grade pulmonary MEC and 12 low-grade. Epidermal growth factor receptor (EGFR) mutation detection was performed in six patients, none was positive. 17 cases was underwent surgery based comprehensive treatment, 12 cases non-operatived treatment. The median follow-up time was 35 (5-114) months in this cohort of 29 patients. During the follow up, incidence of death was found in 17 cases. The overall 1-, 3-, 5-year survival rates were 65.5%, 51.2%, 39.4%, respectively. The median survival time was 37 months.
Conclusions: The incidence of pulmonary MEC is low, lacking specific clinical characterization. The diagnosis mainly depends on postoperative pathology, aided by immunohistochemical. Surgery is the main treatment method. The majority of pathology was high-grade type. The prognosis of pulmonary MEC closely relates to the pathological types and clinical stage. EGFR-tyrosine kinase inhibitor (EGFR-TKI) is expected to improve the prognosis of pulmonary MEC.
背景与目的 肺粘液表皮样癌（mucoepidermoid carcinoma, MEC）是罕见的肺部恶性肿瘤，其临床特征及预后尚不完全明确，本研究旨在探讨肺粘液表皮样癌的临床特征、诊治方法及预后影响因素。方法 回顾郑州大学附属肿瘤医院2006年1月-2015年12月收治的29例肺MEC患者的临床资料，对临床特征、诊断方法、治疗措施及预后进行分析。结果 全组29例患者占同期新诊断肺癌的0.16%（29/18,021），其中男性18例，女性11例；中位年龄45岁（10岁-79岁）；高级别肺MEC 17例，低级别12例。6例患者行表皮生长因子受体（epidermal growth factor receptor, EGFR）基因检测均未检测到突变。行手术为主的综合治疗17例，非手术治疗12例。中位随访时间35（5-114）个月，至随访结束，17例患者已死亡。全组1年、3年、5年生存率分别为65.5%、51.2%和39.4%，中位生存时间37个月。结论 肺MEC发病率低，临床表现缺乏特异性，确诊主要依据术后组织病理，并辅以免疫组化标记结果，手术是主要的治疗方法，病理级别以高级别为主，其预后与组织学分级、临床分期密切相关，EGFR酪氨酸激酶抑制剂（EGFR-tyrosine kinase inhibitor, EGFR-TKI）有望改善肺MEC的预后。.